Although association between the missense variants of the NTRK genes and the development of malignant tumors has not been elucidated, it has been reported that if a tumor has the missense variants of the NTRK genes involving the kinase region, it becomes resistant to TRK inhibitors, larotrectinib, and entrectinib. This evidence concerns the gene NTRK1 and cancer.